XML 18 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Jan. 31, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Registrant Name Magenta Therapeutics, Inc    
Trading Symbol MGTA    
Entity Central Index Key 0001690585    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Ex Transition Period false    
Entity Emerging Growth Company true    
Entity Small Business true    
Entity Shell Company false    
Entity Tax Identification Number 81-0724163    
Entity Public Float     $ 56.3
Title of 12(b) Security Common Stock    
Entity Interactive Data Current Yes    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 100 Technology Square    
Entity Address, City or Town Cambridge    
Entity Address, Postal Zip Code 02139    
Entity Address, State or Province MA    
Entity File Number 001-38541    
City Area Code 857    
Local Phone Number 242-0170    
Entity Common Stock, Shares Outstanding   60,639,909  
ICFR Auditor Attestation Flag false    
Auditor Name KPMG LLP    
Auditor Firm ID 185    
Auditor Location Boston, Massachusetts    
Documents Incorporated By Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Proxy Statement for its 2023 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K.